Launching prescription medicines excellently – achieving optimal commercial performance that reflects a medicine’s value and ...

Merck & Co – known as MSD outside of the US and Canada – has unveiled a new cost-cutting plan aimed at saving $3bn every year by the end of 2027. The annual cost savings generated by the “multi-year ...

Novartis is set to acquire Myricx Bio, paying $1.1bn upfront, with up to $400m in potential milestone payments. The acquisition would strengthen Novartis’ oncology pipeline and advance next-generation ...

Klick Health, a global, independent commercialisation partner for life sciences, has acquired Oxford PharmaGenesis, a ...

Every year, ASCO arrives with a theme. Most quietly disappear into the background by the end of the opening session, overtaken by survival curves, late-breaking data and the relentless pace of ...

Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful ...

Women in Healthcare Leadership podcast series. Now on its fourth series, “Hear from Her” has established itself globally as ...

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and ...

Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies ...

For pharma, its AI progress appears to be slowed by a methodical procession of AI adoption through a series of chicanes.

Zymeworks, a biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of ...